UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1401-4
Program Prior Authorization/Notification
Medication Cuvrior™ (trientine tetrahydrochloride)*
P&T Approval Date 1/2023, 1/2024, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Cuvrior* (trientine tetrahydrochloride) is a copper chelator indicated for the treatment of adult
patients with Wilson’s disease who are de-coppered and tolerant to penicillamine.
2. Coverage Criteriaa:
A. Initial Authorization
1. Cuvrior* will be approved based on all of the following criteria:
a. Diagnosis of Wilson’s disease
-AND-
b. Patient is de-coppered [i.e., serum non-ceruloplasmin copper (NCC) level ≥ 25 and
≤ 150 mcg/L]
-AND-
c. Patient is tolerant to penicillamine
-AND-
d. Patient will discontinue penicillamine before starting therapy with Cuvrior
Authorization will be issued for 12 months.
B. Reauthorization
1. Cuvrior* will be approved based upon the following criterion:
a. Documentation of positive clinical response to Cuvrior therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
*Cuvrior is typically excluded from coverage. Tried/Failed criteria may be in place. Please refer to
plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Cuvrior [package insert]. Chicago, IL: Orphalan; April 2022.
Program Prior Authorization/Notification – Cuvrior (trientine tetrahydrochloride)
Change Control
1/2023 New program.
1/2024 Annual review with no changes to coverage criteria.
2/2024 Annual review. Added footnote indicating Cuvrior is typically
excluded from coverage. Updated authorization durations to 12
months.
2/2025 Annual review with no changes to coverage criteria.
© 2025 UnitedHealthcare Services, Inc.
2